Harry Erba, MD, PhD:So, next we’re going to discuss a 67-year-old woman who goes to her primary care physician with a number of symptoms. She has fatigue, she has abdominal fullness, she has night sweats, and she has been losing weight. She has lost 17 pounds. On her past medical history, she just has hypertension on physical exam. Her spleen tip is palpable, about 7 cm below the left costal margin. Nothing else on exam. In terms of her blood count, she’s anemic with a hemoglobin of 9.2. She has a normal platelet count of 189,000 and she has leukocytosis with a white-blood cell count of 19,000.
So, at that point, you know that the patient has leukocytosis anemia and a big spleen. There’s a very broad differential diagnosis here. And looking at the peripheral blood smear can be very helpful because this could be a patient with chronic lymphocytic leukemia, mantle cell lymphoma, or marginal zone lymphoma. So, lymphomas can present like this. Even hairy cell leukemia can present like this. And so, the peripheral blood smear might be very helpful with that leukocytosis if there are a lot of lymphocytes there and you can perform flow cytometry on the peripheral blood to try to ascertain the diagnosis. Evidently, that was likely not the case because she has a bone marrow biopsy, and the bone marrow biopsy shows class 3, or grade 3, fibrosis in the marrow, myelofibrosis. They do immunostains for CD34 and CD117 and find 1.2% blast in the marrow, and they do a molecular analysis showing that the disease in the marrow is positive for substitution of missense mutation inJAK2called the V617Fmutation. So, the final diagnosis is primary myelofibrosis.
Transcript edited for clarity.
March 2017
Degree of Anemia Influences Therapy for Myelofibrosis
January 23rd 2025During a Case-Based Roundtable® event, Andrew Kuykendall, MD, and participants discussed the the importance of early intervention and consideration of anemia with JAK inhibitor therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Ropeginterferon Alfa-2b Succeeds in Phase 3 Essential Thrombocythemia Trial
January 6th 2025The SURPASS-ET trial demonstrated ropeginterferon alfa-2b's superior efficacy over anagrelide, achieving higher durable response rates and greater reduction in JAK2 allele burden among patients with essential thrombocythemia.
Read More